A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Washington University School, of Medicine, Barnes-Jewish Hospital, St Louis, Missouri University of Utah, Saint Lake City, Utah Age range
18 Years and older
Last updated December 2025